Yuhan Corporation's lung cancer new drug 'Leclaza (ingredient name, lazertinib)' has received sales approval from Chinese health authorities for combination therapy.
According to industry sources on the 31st, the National Medical Products Administration (NMPA) of China recently approved the official marketing of Leclaza. Leclaza is used in combination therapy with the United States' Johnson & Johnson (J&J) 'Rybrevant (amivantamab)' and has previously obtained product approvals in the U.S., Europe, the U.K., Canada, and Japan. It is used for patients with progressive or recurrent unresectable epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).
Yuhan Corporation will receive an additional $45 million (628 million won) in milestone payments according to the approval from Chinese authorities. The milestone payment will be made upon the first administration to a patient.